Oncolys BioPharma Inc. announced on 7 October that it had been included in the constituents of the Tokyo Stock Price Index (TOPIX), and the 24-month stability test results for the oncolytic virus Telomelysin injection were published on the same day or thereafter. Attention is focused on future earnings trends and updates to investor relations information.
Oncolys BioPharma Inc. published an announcement on 7 October regarding its inclusion in the constituents of the Tokyo Stock Price Index (TOPIX). This means that the company's shares will be treated as a constituent of TOPIX.
During the same period, the 24-month stability test results for the oncolytic virus Telomelysin injection were reported to have met the criteria for all items, and a long-term stability assessment was published. This information has attracted investors' attention.
Among market participants, the update to Shikiho's earnings forecast was reported as of 9 October, with some viewing it as potentially affecting the company's future earnings outlook. In response to this investor relations information and the market reaction, attention is also focused on future news releases.
As for stock market trends, price movements following the release of the related news and developments in individual stocks continue to be closely watched, while investors are waiting for formal earnings briefings and the disclosure of additional earnings indicators.